IL37 and systemic lupus erythematosus: Moreover, we and others have reported that IL-37 has synergistic effects with MSCs or ERCs in attenuation of UC [41], intestinal ischemia–reperfusion injury [42], concanavalin A-induced hepatitis [43], and SLE [44] via different mechanisms.